SubsidieMeestersA minimally Invasive surgical platform aGainst paNcreatIc and biliary Tract cancErs using cold atmospheric PLASMA
This project aims to develop a novel cold atmospheric pressure plasma system for minimally invasive treatment of pancreatic and biliary tract cancers, integrating advanced modeling and in-vivo testing.
Projectdetails
Introduction
Cancer is one of the major causes of death in Europe. Pancreatic (PC) and biliary tract (BTC) cancer are rare gastrointestinal adenocarcinomas with an increasing incidence, particularly among the elderly and women in an ageing European population. The poor prognosis of these cancers poses major clinical challenges and a significant public health burden.
Cold Atmospheric Pressure Plasma (CAP)
Cold atmospheric pressure plasma (CAP) has shown potential in regressing various cancer types in laboratory settings. Owing to its properties, CAP is a unique source of high concentrations of reactive radicals, electrons, ions, UV, etc., that may induce various effects in living tissue.
Selectivity of CAP
CAP has demonstrated selectivity in treating cancer cells with minimal effects on healthy ones. This selectivity renders plasma suitable for treating carcinomas in very sensitive areas or organs where there is an unmet need to minimize damage and side effects.
Delivery Mechanism
CAP can be delivered through dielectric tubes of variable length, making it ideal for minimally invasive and precise laparoscopic and endoscopic operations.
Current Market Gap
Despite the great promise and potential of this concept, there is currently no single laparoscopic or endoscopic medical platform in the market based on CAP to treat carcinomas.
Proposed Solution
This project proposes a novel solution using cutting-edge plasma technology, in-silico models, and a system-level approach.
Integration of Technologies
- Combine plasma with tumor multiscale simulations.
- Take input from pre-surgery diagnostics for in-silico model initialization.
- Determine the CAP operational window.
Demonstration and Future Steps
The developed technology will be demonstrated through in-vivo experiments. Additionally, the foundations for clinical trials and market introduction for CAP-based care of PC/BTCs will be laid out in this project.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.792.500 |
| Totale projectbegroting | € 2.792.500 |
Tijdlijn
| Startdatum | 1-4-2024 |
| Einddatum | 31-3-2028 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- UNIVERSITY OF CYPRUSpenvoerder
- SORBONNE UNIVERSITE
- PANEPISTIMIO PATRON
- OGKOLOGIKO KENTRO TRAPEZAS KYPROU
- SYNNOUS LIMITED
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic CancerLASERBLOOD aims to develop a non-invasive blood test using fluorescence lifetime analysis of personalized protein corona to enable early detection of pancreatic cancer, potentially reducing mortality rates significantly. | EIC Pathfinder | € 2.988.461 | 2024 | Details |
MULTIMODE NONLINEAR FIBER BASED ENDOSCOPIC IMAGING AND TREATMENTMULTISCOPE aims to revolutionize optical diagnostics and therapy by developing a dual-function endoscopic device for real-time optical biopsy and cold atmospheric plasma treatment in gastrointestinal care. | EIC Pathfinder | € 2.863.733 | 2024 | Details |
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy. | EIC Pathfinder | € 5.972.875 | 2024 | Details |
Specific Conjugation of Antibodies to Lipid Photo-peroxidised cancer tissues for their immunogenic ELiminationSCALPEL aims to revolutionize cancer treatment by using photodynamic therapy to destroy tumors while marking surviving cells for immune system targeting, potentially offering a curative photoimmunotherapy. | EIC Pathfinder | € 4.554.301 | 2025 | Details |
2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography ApproachPERSEUS aims to develop a novel nanotechnology-based cancer therapy that activates under CT imaging to treat deep-seated, drug-resistant tumors with minimal side effects. | EIC Pathfinder | € 2.740.675 | 2023 | Details |
Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer
LASERBLOOD aims to develop a non-invasive blood test using fluorescence lifetime analysis of personalized protein corona to enable early detection of pancreatic cancer, potentially reducing mortality rates significantly.
MULTIMODE NONLINEAR FIBER BASED ENDOSCOPIC IMAGING AND TREATMENT
MULTISCOPE aims to revolutionize optical diagnostics and therapy by developing a dual-function endoscopic device for real-time optical biopsy and cold atmospheric plasma treatment in gastrointestinal care.
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.
NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.
Specific Conjugation of Antibodies to Lipid Photo-peroxidised cancer tissues for their immunogenic ELimination
SCALPEL aims to revolutionize cancer treatment by using photodynamic therapy to destroy tumors while marking surviving cells for immune system targeting, potentially offering a curative photoimmunotherapy.
2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography Approach
PERSEUS aims to develop a novel nanotechnology-based cancer therapy that activates under CT imaging to treat deep-seated, drug-resistant tumors with minimal side effects.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
SupraTagEen innovatieve hydrogel voor gecontroleerde medicijnafgifte bij peritoneale carcinomatose verbetert de behandeling en vermindert bijwerkingen. | Mkb-innovati... | € 200.200 | 2020 | Details |
Transforming bone cancer therapy with composite biomaterials encapsulating plasma-generated RONSTRANSFORMER aims to develop a novel therapy combining cold atmospheric plasma-treated hydrogels with biomaterials for simultaneous osteosarcoma treatment and bone regeneration, enhancing patient outcomes. | ERC Proof of... | € 150.000 | 2022 | Details |
PRO CellecTPan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren. | Mkb-innovati... | € 20.000 | 2021 | Details |
Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkankerDe ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren. | Mkb-innovati... | € 20.000 | 2020 | Details |
Targeting bicarbonate transport as a “first-in-class” therapeutic strategy to promote CD8+ T cell fitness and enhance cancer immunotherapyThis project aims to develop and commercialize bicarbonate transporter blockers to enhance CD8+ T cell efficacy and improve immunotherapy outcomes in pancreatic cancer. | ERC Proof of... | € 150.000 | 2022 | Details |
SupraTag
Een innovatieve hydrogel voor gecontroleerde medicijnafgifte bij peritoneale carcinomatose verbetert de behandeling en vermindert bijwerkingen.
Transforming bone cancer therapy with composite biomaterials encapsulating plasma-generated RONS
TRANSFORMER aims to develop a novel therapy combining cold atmospheric plasma-treated hydrogels with biomaterials for simultaneous osteosarcoma treatment and bone regeneration, enhancing patient outcomes.
PRO CellecT
Pan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren.
Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkanker
De ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren.
Targeting bicarbonate transport as a “first-in-class” therapeutic strategy to promote CD8+ T cell fitness and enhance cancer immunotherapy
This project aims to develop and commercialize bicarbonate transporter blockers to enhance CD8+ T cell efficacy and improve immunotherapy outcomes in pancreatic cancer.